The biological clock targeted at patients can effectively fight liver cancer

Share This Post

According to a preclinical study by scientists at the University of Texas Health Science Center (UTHealth) in Houston, the circadian body clock plays an important role in fighting liver cancer. The result was recently published in the journal Nature Communications.

The circadian clock is an internal 24-hour timekeeping system that can operate in all cells of the body to regulate sleep, metabolism and other important body functions. Dr. Kristin Eckel-Mahan, a senior author of the study and an assistant professor at the Center for Metabolism and Degenerative Diseases, said, “By manipulating the circadian clock, the growth of liver cancer can be suppressed in a mouse model.

The researchers confirmed their findings in human tissue samples, and Eckel-Mahan ‘s team discovered a dysfunctional protein that inhibits the expression of key circadian rhythm transcription factors and blocks tumor suppressors from performing their actions The ability to function normally for 24 hours. When researchers force tumor cells to re-express the lack of circadian protein, tumor cells die. Eckel-Mahan said that 50% of liver tumors express this dysfunctional protein, causing these cells to develop circadian rhythm dysfunction.

These results indicate that the circadian clock targeting patients with HCC may be a promising treatment for the growth and progression of HCC tumors. The next step is to determine how to prevent the interruption of the circadian clock, and study the pharmacological methods known to improve the function of the circadian clock Can stop the growth of these liver tumors.

http://www.sleepreviewmag.com/2018/11/body-clock-liver-cancer-growth/

Website |  + posts

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Cancer

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
Blood cancer

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new option for treatment after failure of initial therapies. The approval follows the presentation of data from clinical trials showing that this combination improved patient outcomes. This combination is a new strategy in the management of LBCL and provides a greater number of available treatments for those with few choices.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟